Solid Bio’s higher gene therapy dose for Duchenne MD runs smack into a fresh set of safety issues -- shares tumble
Solid Biosciences has just ricocheted into a new setback.A few months after reporting dismal responses from a small cohort of patients receiving its gene therapy for Duchenne muscular dystrophy, the biotech had a chance to increase the dose to what it felt would be an ideal level — and immediately ran into a serious adverse event that had to be reported to the FDA.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
